Doxorubicin‐Loaded Metal–Organic Framework for Ferroptosis‐Enhanced Chemotherapy Through Sustained Zn Release and Glutathione Peroxidase Downregulation
Advanced Healthcare Materials · 2026-03 · 15 (12)
DOI: 10.1002/adhm.202503611 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 04.01.2026. Verfasst von Xin Ma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, The University of Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Ferroptosis, Doxorubicin, Metal-Organic Frameworks, Zinc. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, University of Chicago Medicine Comprehensive Cancer Center, National Cancer Institute.
Themen: Onkologische Pflege
Abstract (Originalsprache)
As a cornerstone of cancer treatment, chemotherapy is frequently hindered by poor tumor specificity, systemic toxicity, and the emergence of drug resistance. These limitations underscore the need for innovative therapeutic strategies that can circumvent resistance mechanisms and enhance cancer cell cytotoxicity. Herein, we report the development of a structurally robust zinc‐based metal–organic framework (ZnMOF) constructed from 4,4′‐di(pyrazol‐4‐yl)‐1,1′‐biphenyl ligands for simultaneous ferroptosis induction and chemotherapeutic delivery. Compared to the widely used ZIF‐8, the newly developed ZnMOF exhibits superior structural stability under physiological conditions, robust doxorubicin (DOX) loading, and pH‐responsive drug release in acidic tumor microenvironments. In addition to efficient DOX delivery, ZnMOF effectively promotes ferroptosis by elevating intracellular reactive oxygen species, depleting glutathione, and inducing lipid peroxidation. In vivo studies using CT26 and MC38 colon carcinoma models demonstrated potent antitumor efficacy of DOX‐loaded ZnMOF, achieving tumor growth inhibition values of 0.91 and 0.93, respectively. These results position ZnMOF as a promising multifunctional nanoplatform for overcoming chemoresistance and enhancing therapeutic outcomes through ferroptosis‐based combination cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, The University of Chicago, Chicago, Illinois, USA.
- Department of Radiation and Cellular Oncology and Ludwig Center For Metastasis Research, The University of Chicago, Chicago, Illinois, USA.
- Department of Chemistry, Westlake University, Hangzhou, Zhejiang, China.
ORCID-Profile: Wenbin Lin
Förderung
- NCI NIH HHS
- University of Chicago Medicine Comprehensive Cancer Center
- National Cancer Institute
Zitieren
APA
Ma, X., Deng, C., Wang, C., Tilman, L., Li, J., & Lin, W. (2026). Doxorubicin‐Loaded Metal–Organic Framework for Ferroptosis‐Enhanced Chemotherapy Through Sustained Zn Release and Glutathione Peroxidase Downregulation. Advanced Healthcare Materials, 15(12). https://doi.org/10.1002/adhm.202503611
Vancouver
Ma X, Deng C, Wang C, Tilman L, Li J, Lin W. Doxorubicin‐Loaded Metal–Organic Framework for Ferroptosis‐Enhanced Chemotherapy Through Sustained Zn Release and Glutathione Peroxidase Downregulation. Advanced Healthcare Materials. 2026;15(12). doi:10.1002/adhm.202503611
BibTeX
@article{Ma2026,
author = {Ma, Xin and Deng, Chenghua and Wang, Chaoyu and Tilman, Langston and Li, Jinhong and Lin, Wenbin},
title = {Doxorubicin‐Loaded Metal–Organic Framework for Ferroptosis‐Enhanced Chemotherapy Through Sustained Zn Release and Glutathione Peroxidase Downregulation},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {12},
doi = {10.1002/adhm.202503611}
}
EUVIMED